• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Rezolute Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    12/10/24 4:43:49 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RZLT alert in real time by email
    false --06-30 0001509261 0001509261 2024-12-05 2024-12-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): December 5, 2024

     

    REZOLUTE, INC.

    (Exact Name of Registrant as Specified in Charter)

     

    Nevada   001-39683   27-3440894

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    275 Shoreline Drive, Suite 500, Redwood City, CA 94065

    (Address of Principal Executive Offices, and Zip Code)

     

    650-206-4507

    Registrant’s Telephone Number, Including Area Code

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report) 

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On December 6, 2024, Rezolute, Inc. (the “Company”) filed with the Secretary of State of the State of Nevada, a Certificate of Amendment to the Amended and Restated Articles of Incorporation of the Company (the “Certificate of Amendment”), which was approved by the Company’s stockholders at the Company’s annual meeting of stockholders held on December 5, 2024 and by written consent of the Company’s board of directors on October 16, 2024.

     

    The Certificate of Amendment increases the Company’s authorized common stock from 100,000,000 shares to an aggregate of 165,000,000 shares. It will not change the total number of shares of Preferred Stock authorized for issuance by the Company.

     

    This summary of the Certificate of Amendment is qualified in its entirety by reference to the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and incorporated by reference herein. A more complete description of the foregoing amendment is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the SEC on October 21, 2024.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    The Company held its 2025 annual meeting of stockholders on December 5, 2024. The meeting was held virtually at RZLT (issuerdirect.com). As of the record date, October 7, 2024, there were a total of 55,927,913 shares of common stock outstanding and entitled to vote at the special meeting. At the annual meeting, 36,588,042 shares of common stock were represented in person (virtually) or by proxy; therefore, a quorum was present. The final voting results for the matters submitted to a vote of stockholders were as follows:

     

    Proposal No. 1 - Election of Directors

     

    To elect the following nominees to serve as members of the Company’s board of directors:

     

    Nominee Name  Votes For   Votes Withheld   Broker Non Votes 
    Nevan Charles Elam   36,573,851    14,191    842,480 
    Young-Jin Kim   34,816,551    1,771,491    842,480 
    Gil Labrucherie   36,090,227    497,815    842,480 
    Philippe Fauchet   36,402,654    185,388    842,480 
    Nerissa Kreher   36,396,819    191,223    842,480 
    Wladimir Hogenhuis   36,402,644    185,398    842,480 

     

    Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm

     

    To ratify Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending on June 30, 2025:

     

    Votes For   Votes Against   Abstentions   Broker Non Votes 
     36,801,947    465,204    163,371    - 

     

    Proposal No. 3 - Say-on-Pay Proposal

     

    To approve by a non-binding advisory vote, the compensation of the Company’s named executive officers, as disclosed in the Executive Compensation section of the proxy statement:

     

    Votes For   Votes Against   Abstentions   Broker Non Votes 
     36,519,454    56,680    11,908    842,480 

     

     

     

     

    Proposal No. 4 – Share Increase Proposal

     

    To approve an amendment to the Company’s Articles of Incorporation to increase the Company’s authorized common stock from 100,000,000 shares of common stock to an aggregate of 165,000,000 shares of common stock:

     

    Votes For   Votes Against   Abstentions   Broker Non Votes 
     36,449,851    134,695    3,496    842,480 

     

    Proposal No. 5 - Equity Plan Amendment Proposal

     

    To approve an amendment to the Company’s 2021 Stock Incentive Plan to increase the number of shares available for issuance thereunder from 10,700,000 shares of common stock to an aggregate of 14,450,000 shares of common stock:

     

    Votes For   Votes Against   Abstentions   Broker Non Votes 
     31,485,706    5,094,003    8,333    842,480 

     

    Proposal No. 6 – Adjournment Proposal

     

    To authorize an adjournment of the meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of the Share Increase Proposal:

     

    Votes For   Votes Against   Abstentions   Broker Non Votes 
     37,186,000    236,512    8,010    - 

     

     

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits. The following Exhibits are furnished as part of this Current Report on Form 8-K.

     

    Exhibit No.   Description
    3.1   Certificate of Amendment, as filed with the Secretary of the State of Nevada on December 6, 2024
    104   Cover Page Interactive Data File (formatted as inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      REZOLUTE, INC.
         
    DATE: December 10, 2024 By: /s/ Nevan Elam
       

    Nevan Elam

    Chief Executive Officer

     

     

     

    Get the next $RZLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RZLT

    DatePrice TargetRatingAnalyst
    3/25/2026$5.00Neutral → Outperform
    Wedbush
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    11/5/2024$12.00Outperform
    Wedbush
    8/27/2024$11.00Buy
    Guggenheim
    7/17/2024$13.00Buy
    BTIG Research
    6/4/2024$14.00Buy
    Craig Hallum
    More analyst ratings

    $RZLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Evans Daron

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/31/26 4:59:51 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth covered exercise/tax liability with 11,439 shares, decreasing direct ownership by 4% to 296,913 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:18:04 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron covered exercise/tax liability with 11,438 shares, decreasing direct ownership by 3% to 404,462 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:16:14 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rezolute upgraded by Wedbush with a new price target

    Wedbush upgraded Rezolute from Neutral to Outperform and set a new price target of $5.00

    3/25/26 8:24:55 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Rezolute from Buy to Hold and set a new price target of $2.00

    12/11/25 3:51:30 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Rezolute from Overweight to Neutral

    12/11/25 12:30:42 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

    REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced outcomes from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI.    In December 2025, the Company reported that sunRIZE demonstrated reductions from baseline in hypoglycemia events, but the study did not meet its primary endpoint because 

    3/24/26 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute to Participate in the Citizens Life Sciences Conference

    REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Citizens Life Sciences Conference, taking place March 10-11, 2026, in Miami, FL. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Citizens representative. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hy

    3/4/26 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

    REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended December 31, 2025. Congenital Hyperinsulinism (HI) In December 2025, Rezolute reported topline results from sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI. The study did not meet its primary or key secondary endpoints. The study demonstrated reductions from baseline

    2/12/26 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:14:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth bought $47,600 worth of shares (28,000 units at $1.70), increasing direct ownership by 10% to 308,352 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:13:53 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron bought $79,578 worth of shares (45,000 units at $1.77), increasing direct ownership by 11% to 415,900 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/15/25 7:35:57 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Rezolute Inc.

    SCHEDULE 13G/A - Rezolute, Inc. (0001509261) (Subject)

    3/26/26 11:07:42 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Rezolute, Inc. (0001509261) (Filer)

    3/24/26 7:30:12 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Rezolute Inc.

    10-Q - Rezolute, Inc. (0001509261) (Filer)

    2/12/26 4:36:52 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Leadership Updates

    Live Leadership Updates

    View All

    Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

    REDWOOD CITY, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced the appointment of Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. "We're thrilled to welcome Sunil to our leadership team at such a pivotal point as we advance ersodetug through Phase 3 studies for both congenital and tumor hyperinsulinism," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "His proven track record of successfully bringing therapies to patients across multiple therapeutic areas, including four ultr

    8/20/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

    sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2025. "The Phase 3 sunRIZE study in congenital HI is on track to complete enrollment this month and we are p

    5/13/25 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

    REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. "We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for p

    3/26/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 10:04:23 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/13/24 5:31:40 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Financials

    Live finance-specific insights

    View All

    Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

    Study did not meet the primary or key secondary endpoint  45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call today at 8:30am ET REDWOOD CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI). The study did not meet its primary endpoint, which assessed change in the average weekly hypoglycemia events by self

    12/11/25 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute to Host Virtual Investor Event on Ersodetug Development Program

    REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that the company will host a virtual investor event via webcast on Monday, November 10, 2025, from 12:00 – 1:30 pm EST. The event will highlight the market opportunity and clinical development of ersodetug, which is currently being evaluated in two Phase 3 studies in congenital hyperinsulinism (HI) and tumor HI, respectively. During the event, Rezolute Chief Commercial Officer, Sunil Karnawat, will discuss the anticipated commercial opportunities for ersodetug as a p

    11/5/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

    Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FDA on unmet need and potential to move into late-stage clinical development to further evaluate RZ358 in this population REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial re

    2/13/24 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care